Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Paracetamol; Metoclopramide hydrochloride
Sanofi
N02BE51
Paracetamol; Metoclopramide hydrochloride
500mg ; 5mg
Effervescent powder
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04070401; GTIN: 5026474000051
of the face, tongue, eyes, neck and affect speech, expression and/or lead to unnatural positioning of the head and shoulders • Decreased level of consciousness, confusion, hallucination • Rigid or stiff muscles, trembling or shaking or difficulty moving • You bruise more easily than usual. This could be because of a blood disorder (thrombocytopenia) • You get infections more often and easier than normal. This could be because you have a low number of white blood cells (agranulocytosis) • Depression TELL YOUR DOCTOR AS SOON AS POSSIBLE IF YOU HAVE ANY OF THE FOLLOWING SIDE EFFECTS: • Diarrhoea • Dizziness, lightheadedness and fainting. This could be because of low blood pressure TELL YOUR DOCTOR OR PHARMACIST IF ANY OF THE FOLLOWING SIDE EFFECTS GET SERIOUS OR LASTS LONGER THAN A FEW DAYS: • Abnormal production of breast milk in men and women • Breast enlargement in men • Loss of menstrual periods • Feeling nervous (anxious), restless or confused • Feeling drowsy • Lack or loss of strength (weakness) • Skin rash REPORTING OF SIDE EFFECTS If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. 5. HOW TO STORE PARAMAX Keep this medicine out of the sight and reach of children. Do not use Paramax after the expiry date which is stated on the sachet and carton after EXP. The expiry date refers to the last day of that month. Store below 25 ° C. Keep the sachets in the outer carton. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. CONTENTS OF THE PACK AND OTHER INFORMATION WHAT PARAMAX CONTAINS • The active substances are metoclopramide hydrochloride and paracetamol. Each sachet con Read the complete document
OBJECT 1 PARAMAX 500MG/5MG EFFERVESCENT POWDER Summary of Product Characteristics Updated 10-Nov-2016 | Zentiva 1. Name of the medicinal product Paramax 500 mg/5 mg Effervescent Powder 2. Qualitative and quantitative composition Each sachet contains 500 mg paracetamol with 5 mg metoclopramide hydrochloride (calculated with reference to anhydrous substance). For the full list of excipients, see section 6.1 3. Pharmaceutical form Effervescent powder 4. Clinical particulars 4.1 Therapeutic indications Adult population Paramax is indicated for the symptomatic treatment of migraine. 4.2 Posology and method of administration Posology Paramax should be taken at the first warning of an attack. If symptoms persist, further doses may be taken at four-hourly intervals. Total dosage in any 24-hour period should not exceed the quantity stated. The dosage recommendations given below should be strictly adhered to if side-effects of the dystonic type are to be avoided. _Usual Recommended Dosage (number of sachets)_ Initial dose at first warning of attack Maximum dosage in any 24- hour period Adults (including elderly patients) 2 6 Treatment should not exceed 3 months due to the presence of metoclopramide (see also sections 4.4 and 4.8). _Paediatric population including adolescents_ Use in children less than 1 year of age is contra-indicated due to increased risk of extrapyramidal disorders (see section 4.4). Use in children and adolescents between the ages of 1 and 18 years is not recommended. Method of administration Paramax sachets are emptied into about 1 / 4 of a glass of water and stirred before taking. For oral administration only. 4.3 Contraindications - Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. - Gastrointestinal haemorrhage, obstruction or perforation, since stimulation of gastrointestinal motility constitutes a risk in these situations. - History of neuroleptic or metoclopramide-induced tardive dyskinesia. - Confirmed epilepsy, since the frequency and severity of seizu Read the complete document